An Outtier

An Outtier

Auto-generated profile, based on publicly available information

An Outtier

Department of Gastroenterology and Hepatology University Hospitals Leuven Leuven Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
WKWannee Kantasiripitak
Wannee Kantasiripitak
AOAn Outtier
An Outtier
SWSebastian Georg Wicha
Sebastian Georg Wicha
AKAlexander Kensert
Alexander Kensert
Zhigang WangZhigang Wang
Zhigang Wang
Erwin DreesenErwin Dreesen
Erwin Dreesen
Infliximab dosage de‐escalation without prior knowledge of drug concentrations may put patients at risk for underexposure and trigger the loss of response. A single‐model approach for model‐informed precision dosing during infliximab maintenance therapy has proven its clinical benefit in patients with inflammatory bowel diseases. We evaluated the predictive performances of two multi‐model approaches, a model selection algorithm and a model averaging algorithm, using 18 published population pharmacokinetic models of infliximab for guiding dosage de‐escalation. Data of 54 patients with Crohn’s disease and ulcerative colitis who underwent infliximab dosage de‐escalation after an earlier escalation were used. A priori prediction (based solely on covariate data) and maximum a posteriori prediction (based on covariate data and trough concentrations) were compared using accuracy and precision metrics and the classification accuracy at the trough concentration target of 5.0 mg/L. A priori prediction was inaccurate and imprecise, with the lowest classification accuracies irrespective of the approach (median 59%, interquartile range 59%–63%). Using the maximum a posteriori prediction, the model averaging algorithm had systematically better predictive performance than the model selection algorithm or the single‐model approach with any model, regardless of the number of concentration data. Only a single trough concentration (preferably at the point of care) sufficed for accurate and precise prediction. Predictive performance of both single‐ and multi‐model approaches was robust to the lack of covariate data. Model averaging using four models demonstrated similar predictive performance with a five‐fold shorter computation time. This model averaging algorithm was implemented in the TDMx software tool to guide infliximab dosage de‐escalation in the forthcoming prospective MODIFI study (NCT04982172).

15 February 2021 in GastroHep
Verified
Journal Article
Open access
PDF file
AOAn Outtier
An Outtier
LWLucas Wauters
Lucas Wauters
JRJean‐Francois Rahier
Jean‐Francois Rahier
PBPeter Bossuyt
Peter Bossuyt
ACArnaud Colard
Arnaud Colard
TGThe Belgian IBD research, Development group
The Belgian IBD research, Development group
Background and Aims Dose intensification of vedolizumab for moderate‐to‐severe ulcerative colitis (UC) and Crohn’s disease (CD) may be effective in patients losing response. We aimed to assess the clinical and pharmacokinetic effect of vedolizumab dose intensification. Methods We performed a multicentre open‐label prospective study from June 2017 through December 2018 in patients on vedolizumab losing response, defined as total Mayo score >6 (UC) or Harvey‐Bradshaw Index >4 with inflammation (CD). Blood samples and clinical scores were collected at Baseline and after vedolizumab‐infusion at Week 4 and 8. Clinical response was defined as a decrease of partial Mayo score ≥2 points or Harvey‐Bradshaw Index ≥3 points. Biological response was defined as a decrease of C‐reactive protein to ≤5 mg/L or of >50%. Results A total of 59 patients (31 UC and 28 CD) were included. Median (IQR) trough levels increased from 8.7 (5.1‐12.7) µg/ml (Baseline) to 19.1 (12.4‐22.4) µg/ml (Week 4) and 23.1 (16.7‐28.4) µg/ml (Week 8) (all p<0.0001). Partial Mayo score decreased with 3 points from Baseline to Week 4 (p=0.001) but stabilised to Week 8 (p=0.16). Harvey‐Bradshaw Index decreased with 4 points from Baseline to Week 4 (p=0.001) and 1 point to Week 8 (p=0.04). Recapture of clinical and biological response was achieved in 49% and 27% at Week 4, and 54% and 37% at Week 8, respectively. Conclusion Dose escalation to vedolizumab every 4 weeks after loss of response resulted in higher trough levels with regain of clinical response in half of the patients.

28 April 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
BVBram Verstockt
Bram Verstockt
VVValery Volk
Valery Volk
CJCharlot Jaeckel
Charlot Jaeckel
DADahham Alsoud
Dahham Alsoud
JSJoão Sabino
João Sabino
KAKonrad Aden
Konrad Aden
Summary: Background: Tofacitinib is the first in class, pan‐JAK inhibitor approved for ulcerative colitis (UC). Clinical efficacy has been shown, but long‐term real‐life endoscopic and histologic data are lacking. Aim: To investigate the effects of tofacitinib in patients with refractory UC focussing on endoscopic, histologic and molecular outcomes, including STAT3 phosphorylation (pSTAT3) detection in the spatial context of mucosal inflammationMethods: We prospectively monitored 59 highly refractory patients (96.7% anti‐TNF exposure, 91.7% vedolizumab exposure) initiating tofacitinib at two IBD referral centres and assessed outcome at the end of induction and after 48 weeks of therapy. Endoscopic improvement was defined as a Mayo endoscopic subscore ≤1, endoscopic and histologic remission as Mayo endoscopic subscore 0 and Nancy histologic score 0. Multiplex immunohistochemistry with multispectral imaging was used to assess pSTAT3.Results: Endoscopic improvement was achieved by 24.4% and 30.5% of patients at weeks 8 and 48, respectively. Endoscopic and histologic remission rates were 11.1%, 23.7 and 16.7%, 21.4%, respectively. Endoscopic improvement at week 8 was significantly associated with treatment continuation in the long‐term (72.7% vs 20.6%, p = 0.003). Although we observed a gradual decrease of mucosal pSTAT3 levels in both remitters and non‐remitters (p < 0.05), no association with treatment outcome could be demonstrated. However, lamina propria pSTAT3 was significantly associated with the Nancy Histologic index (p = 0.004).Conclusion: Tofacitinib can induce and maintain endoscopic and histologic remission in up to one‐quarter of highly refractory UC patients. Longitudinal monitoring of nuclear pSTAT3 in mucosal tissue compartments reflects distinctive on‐target effects, independently of long‐term treatment outcomes.

9 November 2022 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
AOAn Outtier
An Outtier
LGLiese Gijbels
Liese Gijbels
MNMaja Noman
Maja Noman
BVBram Verstockt
Bram Verstockt
JSJoão Sabino
João Sabino
MFMarc Ferrante
Marc Ferrante
Patients with inflammatory bowel diseases (IBD) sometimes require investigational medicinal therapy in a clinical trial. Before enrollment, patients must meet strict eligibility criteria, hampering recruitment rates. We investigated the rates, causes, and outcomes of screening failure (SF) in a tertiary IBD center. We reviewed all IBD patients screened for sponsored multicenter phase 1-3 induction studies with available global SF rates between January 2008 and March 2021. We compared our SF rates with the global SF rates. Causes of SF were categorized into disease activity, hematology, chemistry, microbiology, protocol violation, and withdrawal of consent. Patient outcomes were categorized into rescreening for the same trial, screening for another trial, (re)introduction of commercially available therapy, surgery, or watchful waiting. During the study period, 642 local screenings were performed as part of 53 studies. We identified an overall SF rate of 17.1%, compared with 39.2% in the global study population (P < .00001). Causes of SF at our center included ineligible disease activity (36.4%), microbiology (25.5%), protocol violation (16.4%), withdrawal of consent (9.1%), chemistry (6.4%) and hematology (6.4%). Thirty SFs could have been avoided by prescreening that was more thorough. After SF, 34 patients were rescreened for the same trial, 17 screened for another trial, 38 initiated approved therapy, 9 were referred for surgery, and 12 did not receive further therapy. A significant proportion of IBD patients consenting to clinical trials fail their screening. Main causes of SF are ineligible disease activity and abnormal finding on microbiology. Approximately one-fourth of SFs could have been avoided by prescreening that was more thorough.

19 December 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
AOAn Outtier
An Outtier
RJRosanne Janssens
Rosanne Janssens
LBLiese Barbier
Liese Barbier
JSJoão Sabino
João Sabino
BVBram Verstockt
Bram Verstockt
MFMarc Ferrante
Marc Ferrante
Background: Eligibility criteria in clinical trials have been criticised for being overly restrictive without clinical justification. Objective: We aimed to investigate the types, evolution, and current status of eligibility criteria in clinical trials for inflammatory bowel diseases (IBD). Methods: We performed a clinical trial databank search on clinicaltrials.gov , and included all Phase 3 placebo‐controlled randomised‐controlled trials (RCTs) investigating biologics or small molecules as induction therapy for moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Eligibility criteria were analysed both quantitatively and qualitatively. Results: Fifty‐nine RCTs were identified between the year 2000 and 2022 (30 for CD and 29 for UC). The median (interquartile range) number of eligibility criteria was 44 (38–49), and did not significantly change over the studied time period ( p = 0.26). Qualitative analysis showed that common patient populations, such as older patients, therapy refractory patients, patients with comorbidities, prior malignancies, unclassified IBD type, ulcerative proctitis, stricturing and fistulizing CD, as well as patients with an ostomy, were often excluded. Heterogeneity in eligibility criteria across the different IBD clinical trials was found, such as for disease activity measurement, dosage of concomitant medication, wash‐out period of advanced therapies, and laboratory tests. Conclusion: The median number of eligibility criteria for IBD RCTs did not significantly change over time. The eligibility criteria are however restrictive and complex, limiting the generalisability of efficacy and safety outcomes in daily practice when drugs are approved. Future research is needed to investigate the impact of broadening eligibility criteria to better encompass real‐world practice.

1 May 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
TVTim Vanuytsel
Tim Vanuytsel
RTR Tito
R Tito
Michael CeulemansMichael Ceulemans
Michael Ceulemans
AMA Moens
A Moens
AOA Outtier
A Outtier
JRJeroen Raes
Jeroen Raes
Crohn’s disease (CD) may affect the entire gut but the composition and optimal sampling of the small intestinal microbiome are understudied. We assessed the variation in small intestinal luminal and mucosal microbiota in CD compared to healthy volunteers (HV) and functional dyspepsia (FD) patients. Duodenal biopsies were collected with the Brisbane aseptic biopsy device1 followed by sterile brushing of the lumen/mucus layer. Aseptic ileal biopsies and brushes were also collected in CD patients with synchronous lower endoscopy. Acid- (proton pump inhibitors, PPIs) or immune-suppression (IS) and macro- (erosions/ulcers) and/or microscopic inflammation (CD) were recorded. Contamination was minimised during sample and data processing2 with further analysis at genus level. Microbiota covariates were studied using distance-based redundancy analysis (dbRDA, genus-level Aitchison distance) and PERMANOVA. Alpha-diversity (α) was compared between sampling types (biopsy/brush), disease groups, PPIs (off/on), IS (yes/no) or location (CD). Genera abundance profiles were compared transversally (sampling type) and regionally (CD) with correction for multiple testing (FDR<.1). A total of 99 participants (21 CD, 48 FD and 30 HV) with similar demographics were included. Only sampling type and subject were associated with duodenal community variation (table). Transversal variation was also evident from the more significant clustering for sampling type vs. groups (fig 1). Within CD, sampling type (8.5%) and location (17.8%, both p=.005) but not treatment or inflammation were associated with community variation. Duodenal α-diversity of brushes was lower vs. biopsies (p<2*10–9) and higher in CD vs. controls (fig 2). Compared to untreated subjects, α-diversity was lower with PPI in brushes (fig 3) and higher with IS in biopsies (CD) (fig 4). The 42 differentially abundant genera between sampling types of the duodenum were largely shared between groups vs. only 3 different genera for the ileum (CD). In CD, regional differences were found for 24 genera in brushes vs. only 6 in biopsies, with inflammation driving minor changes in brush and not biopsy samples of the duodenum only. Small intestinal microbiota variation is significant, especially between duodenal luminal and mucosal communities. Luminal α-diversity was highest in CD but lower than that of the mucosa with an effect of treatment. Despite regional variation, mucosal genera profiles were more conserved and less affected by inflammation in CD. References 1. Shanahan et al., AP&T 2016 2. Davis et al., Microbiome 2018